STOCK TITAN

Veracyte (VCYT) general counsel sells 10,204 shares in 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

VERACYTE, INC. senior vice president and general counsel Annie McGuire reported selling a total of 10,204 shares of common stock in open-market transactions on May 6, 2026. The shares were sold in two blocks at $40.00 and $38.05 per share.

After these sales, she directly owns 143,708 shares of Veracyte common stock. According to a footnote, the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2025, indicating they were scheduled in advance.

Positive

  • None.

Negative

  • None.
Insider McGuire Annie
Role SVP, General Counsel
Sold 10,204 shs ($398K)
Type Security Shares Price Value
Sale Common Stock 5,102 $38.05 $194K
Sale Common Stock 5,102 $40.00 $204K
Holdings After Transaction: Common Stock — 148,810 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares sold 10,204 shares Total common shares sold on May 6, 2026
Sale price 1 $40.00 per share Open-market sale of 5,102 shares on May 6, 2026
Sale price 2 $38.05 per share Open-market sale of 5,102 shares on May 6, 2026
Shares owned after trades 143,708 shares Direct common stock ownership following the reported sales
Rule 10b5-1 plan adoption date August 29, 2025 Pre-arranged trading plan governing the May 6, 2026 sales
Rule 10b5-1 plan regulatory
"The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
open-market sale financial
"transaction_action is described as an open-market sale of common stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McGuire Annie

(Last)(First)(Middle)
6000 SHORELINE COURT, SUITE 300

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
SVP, General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/06/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/06/2026S(1)5,102D$38.05148,810D
Common Stock05/06/2026S(1)5,102D$40143,708D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 29, 2025.
Remarks:
/s/ Jonathan Wygant, as attorney-in-fact05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Veracyte (VCYT) report for Annie McGuire?

Veracyte reported that SVP and general counsel Annie McGuire sold 10,204 shares of common stock in open-market transactions. The sales occurred on May 6, 2026 at prices of $40.00 and $38.05 per share, according to the Form 4 filing.

At what prices were the Veracyte (VCYT) insider shares sold?

The insider shares were sold at $40.00 and $38.05 per share. These were open-market transactions executed on May 6, 2026, as disclosed in the Form 4 filed for Veracyte senior vice president and general counsel Annie McGuire.

How many Veracyte (VCYT) shares does Annie McGuire hold after the Form 4 sales?

After the reported transactions, Annie McGuire directly holds 143,708 shares of Veracyte common stock. This post-transaction holding reflects her remaining direct ownership following the sale of 10,204 shares disclosed in the Form 4 filing.

Were the Veracyte (VCYT) insider sales made under a Rule 10b5-1 plan?

Yes. A footnote states the transactions were made pursuant to a Rule 10b5-1 trading plan. The plan was adopted on August 29, 2025, indicating the May 6, 2026 sales were pre-scheduled rather than discretionary trades.

What role does the insider in this Veracyte (VCYT) Form 4 hold?

The reporting person, Annie McGuire, serves as Veracyte’s senior vice president and general counsel. The Form 4 details her open-market sale of 10,204 common shares and her resulting direct ownership of 143,708 shares.